Beyond Air Inc (XAIR) Stock Price, Quote & News

Company Profile

Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiol...

Industry: Medical Devices

Sector: Healthcare

Phone: 516 665 8200

Website: www.beyondair.net

Address:

900 Stewart Avenue, Suite 301, Garden City, United States

SuperGreenToday May. 13 at 12:46 AM

$XAIR

0 · Reply

WallStreetVice May. 12 at 5:45 PM

$XAIR

0 · Reply

WallStreetVice May. 12 at 5:35 PM

$XAIR bullish

0 · Reply

WallStreetVice May. 12 at 5:35 PM

$XAIR 0,7-1$ neext

0 · Reply

Say_Whaaaat May. 12 at 1:14 PM

$XAIR I'm surprised there hasn't even been a weak buyout here. I thought the cancer trial was a big deal only to find out that they only did a half ass study that doesn't really hold water. Then the first version of the machine just sucked and really screwed us over. There hasn't been a buyout because there's not much here.... We were sold a pipe dream. Lol but not lol. Oh well... Expensive lesson learned..

0 · Reply

VernCapital May. 10 at 1:00 PM

$XAIR yes i really should know more about this company 😂😂😂😂

2 · Reply

iNVidiousGeek May. 8 at 10:26 PM

$XAIR Which way is the wind going to blow on this fine product? Signed an agreement with 2,000 hospitals. I believe the wind blows North!

0 · Reply

iNVidiousGeek May. 7 at 8:28 AM

$XAIR I XAIR you to One Doll Hair!

0 · Reply

iNVidiousGeek May. 6 at 10:19 PM

$XAIR Great product, lousy support from management. Maybe they get their act together and higher a PR firm. I believe if they would of made that investment already. We would be sitting at $5.00

1 · Reply

InvestingSpaceman May. 4 at 8:41 PM

$GDC $TCRD $XAIR $XHLD FF

0 · Reply

Beyond Air’s Beyond Cancer reports updated data from Phase 1 UNO trial

Apr 20, 2026, 8:00 AM EDT - 23 days ago

Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026

Apr 15, 2026, 8:00 AM EDT - 4 weeks ago

Beyond Air to Participate in the D. Boral Capital Global Conference 2026

2026-03-26T20:10:58.000Z - 6 weeks ago

Beyond Air CEO Steve Lisi resigns, Robert Goodman succeeds

2026-03-17T20:45:51.000Z - 2 months ago

Beyond Air subsidiary reports signs of clinical activity from UNO trial

Mar 17, 2026, 4:35 PM EDT - 2 months ago

Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial

Mar 12, 2026, 2:30 PM EDT - 2 months ago

Beyond Air Transcript: Life Sciences Virtual Investor Forum

2026-03-10T11:35:43.000Z - 2 months ago

Beyond Air announces termination of NeuroNOS agreement with XTL

XTLB

2026-02-20T13:08:00.000Z - 2 months ago

Beyond Air announces publication of review article on effects of iNO

Feb 20, 2026, 8:00 AM EST - 2 months ago

Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections

2026-02-19T21:31:02.000Z - 2 months ago

Beyond Air price target lowered to $2 from $6 at JonesResearch

Feb 13, 2026, 8:00 AM EST - 3 months ago

Beyond Air Earnings Call Transcript: Q3 2026

2026-02-13T12:36:07.000Z - 3 months ago

Beyond Air reports Q3 EPS (85c) vs ($2.96) last year

2026-02-13T12:36:01.000Z - 3 months ago

Beyond Air sees FY26 revenue $8M-$10M, consensus $8.28M

Feb 13, 2026, 7:30 AM EST - 3 months ago

Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

2026-01-30T21:10:38.000Z - 3 months ago

Beyond Air files to sell 7.86M shares of common stock for holders

2026-01-29T21:40:19.000Z - 3 months ago

XTL Biopharmaceuticals provides update on recent developments

XTLB

Jan 27, 2026, 4:05 PM EST - 3 months ago

Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences

2026-01-20T12:35:20.000Z - 4 months ago

Beyond Air initiated with a Buy at Rodman & Renshaw

Jan 15, 2026, 1:30 PM EST - 4 months ago

Beyond Air Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

2026-01-14T13:45:25.000Z - 4 months ago

Beyond Air prices 3.93M shares at $1.272 in private placement

2026-01-13T13:23:31.000Z - 4 months ago

Why Is Beyond Air Stock (XAIR) Up Today?

XTLB

2026-01-13T12:35:15.000Z - 4 months ago

XTL Biopharmaceuticals to acquire 85% of Beyond Air’s NeuroNOS for $32.5M

XTLB

Jan 13, 2026, 7:30 AM EST - 4 months ago

XTL Biopharmaceuticals Acquires 85% of Beyond Air's Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

2025-12-30T12:45:32.000Z - 4 months ago

Beyond Air appoints Dan Moorhead as CFO

2025-12-17T12:35:22.000Z - 5 months ago

Beyond Air signs new international LungFit PH distribution agreements

2025-11-26T21:35:19.000Z - 5 months ago

Beyond Air announces resignation of CFO Doug Larson

Nov 26, 2025, 4:30 PM EST - 5 months ago

Beyond Air® Announces Transition of Chief Financial Officer

2025-11-21T21:10:28.000Z - 6 months ago

Beyond Air files to sell 1.6M shares of common stock for holders

Nov 10, 2025, 4:30 PM EST - 6 months ago

Beyond Air Earnings Call Transcript: Q2 2026

Nov 10, 2025, 4:05 PM EST - 6 months ago

Beyond Air® Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

Sep 22, 2025, 8:00 AM EDT - 8 months ago

Beyond Air to Participate in the ROTH 4th Annual Healthcare Opportunities Conference

Sep 8, 2025, 3:55 PM EDT - 8 months ago

Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds

Sep 3, 2025, 8:00 AM EDT - 9 months ago

Beyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 8:00 AM EDT - 9 months ago

Beyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in Japan

Aug 12, 2025, 4:30 PM EDT - 9 months ago

Beyond Air Earnings Call Transcript: Q1 2026

Jul 25, 2025, 8:00 AM EDT - 10 months ago

Beyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and Webcast

Jul 22, 2025, 7:30 AM EDT - 10 months ago

Beyond Air Awarded Therapeutic Gases Agreement with Premier, Inc.

Jun 17, 2025, 4:30 PM EDT - 11 months ago

Beyond Air Earnings Call Transcript: Q4 2025

Jun 17, 2025, 4:01 PM EDT - 11 months ago

Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Jun 16, 2025, 8:00 AM EDT - 11 months ago

Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH

May 20, 2025, 8:00 AM EDT - 1 year ago

Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast

Apr 21, 2025, 4:05 PM EDT - 1 year ago

NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism

Apr 15, 2025, 4:05 PM EDT - 1 year ago

NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board

Apr 9, 2025, 4:05 PM EDT - 1 year ago

Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site

Mar 24, 2025, 4:05 PM EDT - 1 year ago

NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy

Mar 11, 2025, 7:30 AM EDT - 1 year ago

Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH

Feb 10, 2025, 4:30 PM EST - 1 year ago

Beyond Air Earnings Call Transcript: Q3 2025

Feb 10, 2025, 4:05 PM EST - 1 year ago

Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

Feb 5, 2025, 9:29 AM EST - 1 year ago

Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

Jan 27, 2025, 4:05 PM EST - 1 year ago

Beyond Air® Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast

Jan 24, 2025, 9:15 AM EST - 1 year ago

Beyond Air® Announces LungFit® PH Receives Market Authorization in Australia

Jan 13, 2025, 10:30 AM EST - 1 year ago

Beyond Air Transcript: Lytham Partners 2025 Investor Healthcare Summit

Dec 9, 2024, 11:00 AM EST - 1 year ago

National Advertising Division Recommends Beyond Air Discontinue or Modify Comparative Safety Claims for its iNO Products

Dec 4, 2024, 4:30 PM EST - 1 year ago

Beyond Air Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 4:05 PM EST - 1 year ago

Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy

Dec 2, 2024, 7:30 AM EST - 1 year ago

Beyond Air Receives CE Mark in Europe for the LungFit® PH System

Nov 26, 2024, 7:30 AM EST - 1 year ago

NeuroNOS Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Advisory Board

Nov 14, 2024, 4:05 PM EST - 1 year ago

Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 11, 2024, 4:30 PM EST - 1 year ago

Beyond Air Earnings Call Transcript: Q2 2025

Nov 11, 2024, 4:05 PM EST - 1 year ago

Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

Oct 29, 2024, 4:22 PM EDT - 1 year ago

Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 2, 2024, 7:30 AM EDT - 1 year ago

Beyond Air Partners with Healthcare Links to Expand Access to LungFit® PH System Through Group Purchasing Organizations and Integrated Delivery Networks

Sep 27, 2024, 7:34 AM EDT - 1 year ago

Beyond Air Provides LungFit® PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed

Sep 27, 2024, 7:32 AM EDT - 1 year ago

Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital

Sep 27, 2024, 7:30 AM EDT - 1 year ago

Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Beyond Air to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Jul 31, 2024, 4:15 PM EDT - 1 year ago

Beyond Air® Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia

Jul 23, 2024, 4:05 PM EDT - 1 year ago

Beyond Air® to Report First Fiscal Quarter 2025 Financial Results on August 6

Jul 16, 2024, 4:05 PM EDT - 1 year ago

Beyond Air® To Participate in the BTIG Virtual Biotechnology Conference 2024

Jun 24, 2024, 4:30 PM EDT - 2 years ago

Beyond Air Earnings Call Transcript: Q4 2024

Jun 24, 2024, 4:15 PM EDT - 2 years ago

Beyond Air® Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Jun 13, 2024, 4:05 PM EDT - 2 years ago

Beyond Air® Appoints David Webster as Chief Commercial Officer

Jun 3, 2024, 7:00 AM EDT - 2 years ago

Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO)

May 23, 2024, 4:09 PM EDT - 2 years ago

Beyond Air® Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast

Mar 20, 2024, 9:00 AM EDT - 2 years ago

Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants

Feb 12, 2024, 4:30 PM EST - 2 years ago

Beyond Air Earnings Call Transcript: Q3 2024

Feb 12, 2024, 4:05 PM EST - 2 years ago

Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024

SuperGreenToday May. 13 at 12:46 AM

$XAIR

0 · Reply

WallStreetVice May. 12 at 5:45 PM

$XAIR

0 · Reply

WallStreetVice May. 12 at 5:35 PM

$XAIR bullish

0 · Reply

WallStreetVice May. 12 at 5:35 PM

$XAIR 0,7-1$ neext

0 · Reply

Say_Whaaaat May. 12 at 1:14 PM

0 · Reply

VernCapital May. 10 at 1:00 PM

$XAIR yes i really should know more about this company 😂😂😂😂

2 · Reply

iNVidiousGeek May. 8 at 10:26 PM

$XAIR Which way is the wind going to blow on this fine product? Signed an agreement with 2,000 hospitals. I believe the wind blows North!

0 · Reply

iNVidiousGeek May. 7 at 8:28 AM

$XAIR I XAIR you to One Doll Hair!

0 · Reply

iNVidiousGeek May. 6 at 10:19 PM

$XAIR Great product, lousy support from management. Maybe they get their act together and higher a PR firm. I believe if they would of made that investment already. We would be sitting at $5.00

1 · Reply

InvestingSpaceman May. 4 at 8:41 PM

$GDC $TCRD $XAIR $XHLD FF

0 · Reply

uptrend2025 May. 4 at 8:26 PM

$XAIR This one popped out of nowhere. 👀

0 · Reply

DirtDobber May. 4 at 7:46 PM

$XAIR what’s deal here lol , patients

0 · Reply

BobintheBuff May. 4 at 5:58 PM

$XAIR did I miss something? Good action today. Maybe we’re getting close to FDA approval of 2.0?

1 · Reply

BillionerOfKing Apr. 27 at 9:42 PM

$XAIR Current Stock Price: $0.49

1 · Reply

VernCapital Apr. 25 at 11:14 AM

$XAIR another R/S …at 20:1 I’ll just need it to get to $720…to break even 😂🤦🏻‍♂️

1 · Reply

Say_Whaaaat Apr. 24 at 9:00 PM

$XAIR another RS vote in early May. 2:1 to 20:1... If they do 20, there will only be 500k float. Lol but not lol. Maybe with Lisi gone people will give it a second look...

1 · Reply

DirtDobber Apr. 23 at 9:08 PM

$XAIR

1 · Reply

VernCapital Apr. 21 at 7:43 PM

$XAIR

0 · Reply

Fufat Apr. 20 at 4:59 PM

$XAIR With all the current news and it drops.... I wonder how many shares are shorted? How deep is it shorted?

1 · Reply

domarffm Apr. 20 at 12:55 PM

$XAIR Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026 https://www.beyondair.net/news-events/press-releases?i=164083

0 · Reply

DARKP00L Apr. 20 at 12:31 PM

$XAIR 08:13 on Apr. 20 2026 Beyond Air Subsidiary Beyond Cancer Announces Updated Follow-Up Data From Its Phase 1 UNO Trial, Notes That As Of February 2, Six Of Ten Patients Remain Alive 22-40 Months After A Single UNO Injection #tradeideas

0 · Reply

Say_Whaaaat Apr. 20 at 12:15 PM

$XAIR here is the poster from the weekend... https://beyondcancer.com/hubfs/AACR2026_304_BeyondCancer_Final.pdf?hsLang=en

0 · Reply

Market Cap	6.86M
Revenue (ttm)	3.71M
Net Income (ttm)	-46.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,256.87%
Debt to Equity Ratio	2.65

Volume	303,600
Avg Vol	315,856
Day's Range	N/A - N/A
Shares Out	13.19M
Stochastic %K	66%
Beta	0.30
Analysts	Strong Sell
Price Target	$6.00